Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amid Pricing Criticism, Marathon 'Pausing' Emflaza Launch

Executive Summary

Company plans to meet with caregivers and consider other options before moving forward.

You may also be interested in...



At Paragon, Jeffrey Aronin Has Launched His Next Act – Or Eight Of Them

Jeffrey Aronin, who presided over Marathon Pharmaceuticals during a drug-pricing kerfuffle that drew congressional scrutiny, has built a portfolio of new drug companies at Paragon Biosciences.

Best Defense Is Good Offense: PhRMA Wants PBMs To 'Share The Savings'

PhRMA ad campaign targets US payer practice of using drug rebate dollars for general premium and cost sharing reductions and not to lower the cost of specific prescription fills.

Allergan Exits Noctiva Partnership With Serenity Just As FDA Approves Controversial Drug

Just as Noctiva obtains FDA approval as the first drug for nocturia due to nocturnal polyuria, Allergan bails on collaboration signed seven years ago.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1134940

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel